Ratings by William Blair (Andrew Brackmann)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | Biodesix | BDSX | Upgrade | Outperform (Market Perform) |
12.93 (18.78) |
45.24% | Details | |
| 1/12/2026 | Exagen | XGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Owlet Inc. | OWLT | New Coverage | Outperform (N/A) |
14.59 (7.26) |
-50.24% | Details | |
| 12/1/2025 | BillionToOne Inc | BLLN | New Coverage | Outperform (N/A) |
130.18 (73.51) |
-43.53% | Details | |
| 11/21/2025 | Exact Sciences | EXAS | Downgrade | Market Perform (Outperform) |
86.18 (103.50) |
20.1% | Details | |
| 11/19/2025 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/26/2025 | CareDx, Inc | CDNA | New Coverage | Market Perform (N/A) |
12.97 (17.89) |
37.93% | Details | |
| 8/7/2025 | Veracyte, Inc | VCYT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2025 | Neogenomics | NEO | Downgrade | Market Perform (Outperform) |
6.46 (8.96) |
38.7% | Details | |
| 7/10/2025 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2025 | Butterfly Network | BFLY | New Coverage | Outperform (N/A) |
2.68 (3.65) |
36.19% | Details | |
| 10/1/2024 | Aldeyra Therapeutics | ALDX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Quidel Corp. | QDEL | Downgrade | Market Perform (Outperform) |
66.77 (20.83) |
-68.8% | Details | |
| 9/12/2023 | Sight Sciences Inc. | SGHT | Downgrade | Market Perform (Outperform) |
6.14 (6.15) |
0.16% | Details | |
| 3/24/2023 | MDxHealth SA | MDXH | New Coverage | Outperform (N/A) |
2.86 (3.27) |
14.34% | Details | |
| 11/4/2022 | DermTech Inc. | DMTK | Downgrade | Market Perform (Outperform) |
3.00 (0.09) |
-97% | Details | |
| 2/3/2022 | Sight Sciences Inc. | SGHT | New Coverage | Outperform (N/A) |
14.94 (3.71) |
-75.17% | Details |
